Jack D Chan, Christina M Scheffler, Isabelle Munoz, Kevin Sek, Joel N Lee, Yu-Kuan Huang, Kah Min Yap, Nicole Y L Saw, Jasmine Li, Amanda X Y Chen, Cheok Weng Chan, Emily B Derrick, Kirsten L Todd, Junming Tong, Phoebe A Dunbar, Jiawen Li, Thang X Hoang, Maria N de Menezes, Emma V Petley, Joelle S Kim, Dat Nguyen, Patrick S K Leung, Joan So, Christian Deguit, Joe Zhu, Imran G House, Lev M Kats, Andrew M Scott, Benjamin J Solomon, Simon J Harrison, Jane Oliaro, Ian A Parish, Kylie M Quinn, Paul J Neeson, Clare Y Slaney, Junyun Lai, Paul A Beavis, Phillip K Darcy
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma1-4 , but the efficacy of CAR T cell therapy in solid tumours has been limited5 . This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more 'stem-like' phenotype and increased mitochondrial mass6-8 ...
April 10, 2024: Nature